A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
NCT06481306
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Anemia, Sickle Cell
- Healthy Volunteers
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Bristol-Myers Squibb
- Last updated on ClinicalTrials.gov
- August 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- University of Alabama at Birmingham · Birmingham, AL
California · 2
- University of California San Diego - La Jolla · La Jolla, CA
- UCSF Benioff Children's Hospital Oakland · Oakland, CA
Connecticut · 1
- Yale-New Haven Hospital · New Haven, CT
Georgia · 1
- Winship Cancer Institute of Emory University · Atlanta, GA
Massachusetts · 1
- Boston Medical Center · Boston, MA
Pennsylvania · 1
- Thomas Jefferson University - Medicine/GI and Hepatology · Philadelphia, PA
Virginia · 2
- Inova Schar Cancer Institute · Fairfax, VA
- Virginia Commonwealth University (VCU) Medical Center · Richmond, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.